Title: One-year therapeutic effect of Entecavir for treating chronic hepatitis B
Abstract: Objective To evaluate the efficacy of Entecavir(ETV) for patients of chronic hepatitis B.Method The 44 patients were divided into HBeAg positive group(24 cases) and HBeAg negative group(20 cases) according to the results of HBV serology,and were administered with ETV 0.5mg,po,qd× 48weeks.After 2,4,8,24 and 48weeks,HBVDNA level(measured by fluorescent quantitative PCR) and liver function were tested.Result Significant reduction of HBVDNA could be detected by PCR assay after 2 weeks of treatment,the mean reduction in serum HBV DNA from baseline to week 2 were 1.5522log10 in HBeAg positive group and 1.6207log10 in HBeAg negative group(P0.001);the ALT and AST reduced significantly also.After 4weeks,the rate of liver function returning to normal level were 14/24 in HBeAg positive group and 14/20 in HBeAg negative group(P =0.4231).Undetectable serum HBVDNA levels were observed in 12 cases(HBeAg-positive group) and 14 cases(HBeAg-negative group)(P =0.1791).At 8th week,almost the patients' liver function returned to normal levels;Undetectable serum HBVDNA levels were observed in 17 cases(HBeAg-positive group) and 19 cases(HBeAg-negative group)(P=0.038).After 24weeks,the serum HBVDNA was undetectabale in all the patients.Conclusion ETV is a potent and selective guanosine analogue with significant activity against HBV.
Publication Year: 2009
Publication Date: 2009-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot